全球药物输送技术市场 – 行业趋势及 2029 年预测

药物输送技术的市场分析与见解

药物输送技术市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析该市场在上述预测期内的复合年增长率为 7.65%。

药物输送基本上是通过常见的给药途径施用治疗物质以达到对人类或动物的治疗效果的过程。药物输送技术控制药物在体内释放的速率和时间，从而提高药物的疗效。

全球慢性病病例和患病率的不断增长以及庞大的患者群体是推动上述预测期内药物输送技术市场增长的重要因素。此外，临床试验数量的增加、该地区主要参与者的投资增加以及劳动力成本低廉等因素也促进了市场的整体增长。然而，药物的副作用和产品召回阻碍了市场的增长。针刺伤和副作用的风险也估计是阻碍市场整体增长的制约因素。

先进新产品的推出和技术的进步有望为市场创造盈利机会。另一方面，熟练专业人员的缺乏可能会对市场的增长构成挑战。

This drug delivery technology market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research drug delivery technology market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Drug Delivery Technology Market Scope and Market Size

Drug delivery technology market is segmented on the basis of route of administration and facility of use. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on route of administration, the market is segmented into oral drug delivery, pulmonary drug delivery, injectable drug delivery, ocular drug delivery, nasal drug delivery, topical drug delivery implantable drug delivery and transmucosal drug delivery. The oral drug delivery is sub-segmented into solid oral drugs, liquid oral drugs and semi-solid oral drugs. The solid oral drugs are sub segmented into tablets, capsules, powders and pills. The liquid oral drugs are sub segmented into solutions and syrups. The semi-solid oral drugs are further sub segmented into gels, emulsions and elixirs. The pulmonary drug delivery is sub-segmented into formulations and devices. The devices are further sub segmented into metered dose inhalers, dry powder inhalers and nebulizers. The nebulizers are sub segmented into jet nebulizers, ultrasonic nebulizers and soft mist nebulizers. The injectable drug delivery is sub-segmented into devices, self-injection devices and other injector devices. The conventional injection devices are sub segmented into material, glass, plastic, product and usability. The product is segmented into fillable syringes and prefilled syringes. The usability is segmented into reusable syringes and disposable syringes. The self-injection devices are sub segmented into needle-free injectors, autoinjectors, pen injectors and wearable injectors. The formulations are divided into conventional drug delivery, novel drug delivery formulations and long-acting injection formulations. The ocular drug delivery is sub-segmented into formulations and ocular devices. The formulations are further sub divided into liquid formulations and semi-solid formulations. The liquid formulations are divided into eye drops and liquid sprays. The semi-solid formulations consist of gels and eye ointments. The ocular devices consist of drug-coated contact lenses and ocular inserts. The nasal drug delivery is sub-segmented into nasal drops, nasal sprays, nasal powders and nasal gels. Under topical drug delivery it is segmented into formulations and devices (transdermal drug delivery). The formulations liquid is sub- segmented into topical drug delivery, semi-solid topical drug delivery and solid topical drug delivery. The liquid topical drug delivery is again sub segmented into solutions and suspensions. The semi-solid topical drug delivery is sub-segmented into creams, gels, ointments, pastes and lotions. The solid topical drug delivery is segmented into suppositories and powders. The devices are sub-segmented into transdermal patches and transdermal gels. Implantable drug delivery is sub-segmented into active implantable drug delivery and passive implantable drug delivery. The transmucosal drug delivery is sub-segmented into oral transmucosal drug delivery and other transmucosal drug delivery. The oral transmucosal drug delivery is further sub-segmented into buccal drug delivery and sublingual drug delivery whereas the other transmucosal drug delivery is further sub-segmented into rectal transmucosal drug delivery and vaginal transmucosal drug delivery.
• On the basis of facility of use, the global drug delivery technology market is segmented into hospitals, ambulatory surgical centers/clinics, home care settings, diagnostic centers and other facilities of use.

Drug Delivery Technology Market Country Level Analysis

Drug delivery technology market is analyzed and market size insights and trends are provided by route of administration and facility of use as referenced above.

The countries covered in the drug delivery technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the high prevalence of chronic diseases such as cancer, cardio vascular diseases, diabetes, respiratory diseases and ongoing technological advancements in drug delivery technology in the region. Asia-Pacific, on the other hand is expected to show a rapid and lucrative growth rate in the forecast period owing to the funds allocated by top companies in the field of R&D activities along with low prices of clinical trials and labor.

药物输送技术市场报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。消费量、生产地点和产量、进出口分析、价格趋势分析、原材料成本、下游和上游价值链分析等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

药物输送技术市场还为您提供每个国家/地区资本设备医疗支出增长、药物输送技术市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对药物输送技术市场的影响的详细市场分析。数据涵盖 2010 年至 2020 年的历史时期。

竞争格局和药物输送技术市场份额分析

药物输送技术市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对药物输送技术市场的关注有关。

药物输送技术市场报告中的一些主要参与者包括强生私人有限公司、罗氏公司、默克夏普和多姆公司、拜耳公司、辉瑞公司、诺华公司、3M、BD、葛兰素史克公司、赛诺菲、Antares Pharma、generex、EyePoint Pharmaceuticals Inc.、Alkermes.、Vectura Group plc、NanoPass、百特、阿斯利康和武田制药有限公司等。

SKU-21345